Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| BOLD | 3 | neutral | 3/10 | Kevin Tang and Tang Capital Management LLC filed a Form 3 initial statement of beneficial ownership, disclosing 2,247,51 | Jul 3, 2026 |
| VTGN | 8-K | bearish | 7/10 | Vistagen announced that its PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder failed to meet the primar | Jul 3, 2026 |
| MBRX | 8-K | bullish | 7/10 | Moleculin Biotech announced positive preliminary unblinded efficacy results from the first 45 patients in Part A of the | Jul 3, 2026 |
| HRMY | 144 | bearish | 5/10 | Former officer Sandip Kapadia filed a Form 144 notice to sell 50,000 shares of Harmony Biosciences, valued at approximat | Jul 3, 2026 |
| IFRX | 6-K | bullish | 6/10 | InflaRx announced it is assessing a broadened development and registrational strategy for ANCA-associated vasculitis (AA | Jul 3, 2026 |
| ASND | 6-K | bullish | 6/10 | Ascendis Pharma announced Week 104 radiographic data from the pivotal ApproaCH trial of TransCon CNP (navepegritide) in | Jul 3, 2026 |
| XERS | 8-K | neutral | 2/10 | Xeris Biopharma announced routine board governance changes: CEO John Shannon was appointed Chair of the Board, Marla Per | Jul 3, 2026 |
| PYXS | 144 | neutral | 2/10 | Director Jakob Dupont filed a Form 144 on June 30, 2026, indicating intent to sell 35,000 shares of Pyxis Oncology commo | Jul 3, 2026 |
| AAPG | 6-K | neutral | 3/10 | Ascentage Pharma granted a total of 4,354,473 equity awards on June 29, 2026 under its 2021 RSU, 2022 RSU, and Post IPO | Jul 3, 2026 |
| IRON | 8-K | neutral | 4/10 | Disc Medicine amended its existing loan agreement with Hercules Capital, drawing $30M from Tranche 1-B and restructuring | Jul 3, 2026 |
| ROIV | 144 | neutral | 3/10 | Director Keith S. Manchester filed a Form 144 notice of intent to sell 200,000 ROIV shares with an estimated aggregate v | Jul 3, 2026 |
| TENX | 8-K | neutral | 4/10 | Tenax Therapeutics entered into a Supply Agreement with Orion Corporation for the manufacture and supply of its orally a | Jul 3, 2026 |
| IMNN | 8-K | neutral | 3/10 | Imunon's interim CFO Jeffrey Church is retiring effective July 1, 2026, and will remain as a consultant at a $10,000 mon | Jul 3, 2026 |
| KYMR | 144 | bearish | 4/10 | Officer Bruce N. Jacobs filed a Form 144 notice of intent to sell 77,109 shares of Kymera Therapeutics common stock, wit | Jul 3, 2026 |
| RAPP | 144 | neutral | 2/10 | Cheryl Gault, an officer of Rapport Therapeutics, filed a Form 144 on June 30, 2026, indicating intent to sell 10,000 sh | Jul 3, 2026 |
| NVCT | 8-K | bearish | 6/10 | Nuvectis Pharma priced a $100 million public offering of 5 million shares at $20 per share, a 30% discount to the prior | Jul 3, 2026 |
| CPRX | 8-K | neutral | 4/10 | Catalyst Pharmaceuticals announced topline results from a Phase 1 study of vamorolone (AGAMREE) showing balanced cortico | Jul 3, 2026 |
| RCKT | 8-K | neutral | 2/10 | Rocket Pharmaceuticals disclosed the resignation of VP of Finance and Principal Accounting Officer John Militello, effec | Jul 3, 2026 |
| NVO | COURT-RULING | bullish | 5/10 | Novo Nordisk's lawsuit against Axtell's Rite-Value Pharmacy for selling unapproved compounded semaglutide drugs survived | Jul 3, 2026 |
| BIAF | 8-K | bullish | 5/10 | bioAffinity Technologies released a Q2 2026 newsletter announcing CyPath Lung unit sales in April increased nearly 300% | Jul 3, 2026 |
| GELS | 6-K | bearish | 7/10 | Gelteq's 6-K filing for H1 FY2026 reveals a critical liquidity crisis: cash and cash equivalents collapsed to just AUD $ | Jul 3, 2026 |
| MESO | 6-K | bullish | 6/10 | Mesoblast received a BLA filing number from the FDA and requested a modular review for rexlemestrocel-L in end-stage hea | Jul 3, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a Form 6-K on July 1, 2026, solely to submit an application for quotation of securities (ATH | Jul 3, 2026 |
| APTOF | 15-12G | bearish | 7/10 | Aptose Biosciences Inc. filed a Form 15-12G to terminate its SEC registration under Section 12(g), effective July 1, 202 | Jul 3, 2026 |
| ZURA | 8-K | neutral | 4/10 | Zura Bio filed an 8-K furnishing an updated corporate presentation (Exhibit 99.1) for investor meetings. The presentatio | Jul 3, 2026 |
| RDHL | 6-K | neutral | 4/10 | RedHill Biopharma filed a 6-K rescheduling its annual general meeting to August 6, 2026, and providing updated proxy mat | Jul 3, 2026 |
| CANF | 6-K | bullish | 5/10 | Can-Fite BioPharma announced positive Phase 2a results for Namodenoson in advanced pancreatic cancer, achieving the prim | Jul 3, 2026 |
| IBIO | 8-K | bullish | 6/10 | iBio reported new preclinical NHP data for its Activin E antibody candidate IBIO-610, showing 98% target inhibition at w | Jul 3, 2026 |
| EVAX | 6-K | neutral | 3/10 | Evaxion announced a poster presentation of preclinical data for its CMV vaccine candidate EVX-V1 at the International He | Jul 3, 2026 |
| HCM | 6-K | bullish | 7/10 | HUTCHMED (HCM) announces conditional NMPA approval in China for ORPATHYS (savolitinib) to treat MET-amplified advanced g | Jul 3, 2026 |